# A Study of JMT203 in Patients With Cancer Cachexia

Source: https://onco.cc/trials/nct06868849/  
OnCo record `nct06868849` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of JMT203 Injection in non-small-cell lung cancer, pancreatic ductal adenocarcinoma and colorectal cancer, run by Shanghai JMT-Bio Inc., now recruiting.

## Summary

A Study of JMT203 in Patients With Cancer Cachexia is a phase 1/2 interventional study registered as NCT06868849 by Shanghai JMT-Bio Inc., with 307 participants planned, started 2024-05-15 and due to reach its primary completion in 2027-08-14. Interventions recorded: JMT203 Injection.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06868849
- Phase: 1/2
- Setting: A Phase Ia/II, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of JMT203 in Patients With Cancer Cachexia
- Sponsor: Shanghai JMT-Bio Inc.
- Enrolled: 307

## Sources

- ClinicalTrials.gov NCT06868849: https://clinicaltrials.gov/study/NCT06868849

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- companies: [CSPC Pharmaceutical Group](https://onco.cc/companies/cspc/)
- drugs: [JMT203](https://onco.cc/drugs/jmt203/)

---
JSON: https://onco.cc/api/v1/entities/nct06868849.json